ESC-HFA 2023 – Late-breaker host, Dr Harriette Van Spall (McMaster University, CA) joined by Dr James Januzzi (Massachusetts General Hospital, US) to discuss late-breaking science highlights of this year's ESC Heart Failure.
Trials covered in details include:
1:13: First-in-Human Study of NI006 in Patients With Amyloid Transthyretin Cardiomyopathy
1:42: TRACER-HF: Trientine-HCL for treatment of heart failure and reduced ejection fraction
2:47: MONITOR-HF: Randomised comparison of the effect of haemodynamic monitoring with CardioMEMS in addition to standard care on quality of life and hospitalisations in patients with chronic heart failure
5:12: DAPA-RESIST: DAPAgliflozin Versus Thiazide Diuretic in Patients With Heart Failure and Diuretic RESISTance
6:46: TRANSFORM-HF:ToRsemide compArisoN With furoSemide FORManagement of Heart Failure
7:44: PARAGLIDE-HF: Changes in NT-proBNP, Safety, and Tolerability in HFpEF Patients With a WHF Event (HFpEF Decompensation) Who Have Been Stabilized and Initiated at the Time of or Within 30 Days Post-decompensation
9:58: PACT-HF: Patient-centered Care Transitions in Heart Failure: A Pragmatic Cluster Randomized Trial
12:16: PROMPT-AHF: Pragmatic trial of messaging to providers about treatment of acute heart failure
Recorded on-site at HFA 2023, Prague.
Explore more content from the ESC Heart Failure 2023 Late-breaking Science Collection.
Editor: Mirjam Boros
Video Specialist: Tom Green, Oliver Miles